Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Valneva SENASDAQ: VALN

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization remains negative

Q1 FY2026 depreciation & amortization was €0, compared with €3.68M a year earlier. Trailing-twelve-month depreciation & amortization was €6.46M. Over 3 fiscal years it compounded at +1.1% a year.

Context

  • Depreciation & amortization amounted to 12.5% of revenue in FY2025, up 0.9 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly depreciation & amortization holds near €0 or moves back toward the trailing-twelve-month quarterly average of €1.61M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€0-100.0% QoQ
Last fiscal yearDec 2025
€21.75M+11.0% YoY
LTMMar 2026
€6.46M-64.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+11.0%——
3-year CAGR+1.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

EUR · from the income statement

Latest · FY2025
21.75M EUR
Year-over-year change
+11.0%
4-year CAGR
+11.1%

Depreciation & Amortization vs competitors

How VALN compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -64.9% is the lowest of 8, against a peer median of -3.9%.
  • Depreciation & amortization amounts to 4.1% of revenue for VALN, versus a peer median of 9.1%.
VALN Competitors
Depreciation & Amortization for VALN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$257M USD+23.6%-14.8%10.2%
PCVXVaxcyte, Inc.LTM Jun 2026$26.8M USD+40.0%+38.0%—
NVAXNovavax, Inc.LTM Mar 2026$22.34M USD-50.0%-1.7%3.7%
IBRXImmunityBio, Inc.LTM Sep 2026$16.54M USD+4.6%-5.3%9.1%
VIRVir Biotechnology, Inc.LTM Mar 2026$11.62M USD-10.0%+19.9%17.7%
VALNValneva SELTM Mar 2026€6.46M EUR-64.9%+1.1%4.1%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$2.99M USD-3.9%-18.4%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$2.88M USD-16.2%+25.6%6.4%
Peer median (excluding VALN) —-3.9%-1.7%9.1%

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue348.09M361.3M153.71M169.58M174.66M
Cost of Revenue187.92M324.44M100.88M98.54M107.14M
Gross Profit160.17M36.86M52.84M71.04M67.52M
Gross Margin46.0%10.2%34.4%41.9%38.7%
Research & Development173.28M104.92M59.89M74.14M85.3M
Selling, General & Admin71.25M57.58M96.55M95.11M74.68M
Operating Expenses221.56M150.31M134.92M57.71M149.15M
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
EBITDA(38.74M)(104.73M)(57.72M)32.08M(50.47M)
EBITDA Margin-11.1%-29.0%-37.6%18.9%-28.9%
Operating Income(61.39M)(113.44M)(82.09M)13.33M(81.63M)
Operating Margin-17.6%-31.4%-53.4%7.9%-46.7%
Interest Income249K260K1.21M2.36M1.8M
Interest Expense16.96M19.05M23.33M23.98M41.9M
Other Income / Expenses(8.59M)(31.37M)(16.54M)(24.82M)(32.49M)
Income Before Tax(69.98M)(144.82M)(98.63M)(11.49M)(114.12M)
Pre-Tax Margin-20.1%-40.1%-64.2%-6.8%-65.3%
Income Tax Expense3.45M(1.54M)2.8M761K1.07M
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Net Margin-21.1%-39.7%-66.0%-7.2%-66.0%
EPS (Basic)(1.50)(2.48)(1.46)(0.17)(1.32)
EPS (Diluted)(1.50)(2.48)(1.46)(0.17)(1.32)
Weighted Avg Shares48.81M57.74M69.47M70.26M84.09M
Weighted Avg Shares (Diluted)48.81M57.74M69.31M70.26M84.09M

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.